DKK2 and neoplasm: It is known that DKK2 antagonizes Wnt signaling [54], thus, inactivation of DKK2 increases Wnt activity with accelerating tumor progression, and activation of the Wnt/β-catenin pathway has been documented in NSCLC [55].